DNA repair in cancer therapy : molecular targets and clinical applications /

Cancer therapeutics include an ever-increasing array of tools at the disposal of clinicians in their treatment of this disease. However, cancer is a tough opponent in this battle, and current treatments, which typically include radiotherapy, chemotherapy and surgery, are not often enough to rid the...

Full description

Saved in:
Bibliographic Details
Other Authors: Kelley, Mark Richard, 1957-
Format: Electronic eBook
Language:English
Published: Amsterdam ; Boston : Academic Press, 2012.
Subjects:
Online Access:CONNECT
Table of Contents:
  • Introduction and Overview of Current Targets: Bench to Clinic / Mark R. Kelley
  • 2. MGMT a Critical DNA Repair Gene Target for Chemotherapy Resistance / Stanton L. Gerson and Lili Liu
  • 3. Blockade of Base Excision Repair: Inhibitionof Small Lesions Results in Big Consequences to Cancer Cells / Melissa Fishel and Carlo Vascotto
  • 4. PARP Inhibitors
  • Scientific Rationale and Clinical Development for Cancer / Ruth Plummer, Nicola J. Curtin and Yvette Drew
  • 5. Inhibiting Selective DNA Polymerases for Therapeutic Intervention / Anthony J. Berdis
  • 6. Targeting the Nucleotide Excision Repair Pathway for Therapeutic Applications / John Turchi and Stephan M. Patrick
  • 7. Homologous Recombination and ATM/ATR Targets / Henning Willers, Lee Zou and Heike N. Pfaffle
  • 8. DNA Double Strand Break Repair by Nonhomologous End Joining and its Clinical Relevance / Michael Weinfeld and Susan Lees-Miller
  • 9. Defective MMR-c-Abl-p73-GADD45alpha Expression in Cancer Chemoresistance / David Boothman and Long Shan Li
  • 10. DNA Repair Signaling Targets / Susan Ashwell
  • 11. Redox Regulation of DNA Repair and Therapeutic / Millie M. Georgiadis
  • 12. Personalized Cancer Medicine: DNA Repair Alterations is a Promising Predictive Marker in Cancer / Srinivasan Madhusudan
  • 13. The Role of DNA Damage and Repair in Neurotoxicity Caused by Cancer Therapies / Michael R. Vasko
  • 14. Future Directions / Mark R. Kelley.